Regeneron Pharmaceuticals

REGN · NASDAQ · USD

$735.20+0.05%+$0.39

Close · October 2, 2026

At a glance

Revenue growth
+0.99%
2025 vs 2024
Net income growth
+2.09%
2025 vs 2024
Net margin
31.4%
2024: 31.1%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total assets41,73140,86940,55940,16938,21937,54537,75937,44236,08734,37033,08032,163
Current assets18,44618,20918,02217,98116,86017,57218,66119,33419,08218,87219,47918,635
Cash and equivalents2,4562,9633,1182,5061,9963,0902,4882,0121,9212,6022,7302,152
Short-term investments5,5395,7915,4875,9375,4745,2596,5247,7857,8887,9188,1157,761
Receivables6,5655,7315,7415,6875,6105,5616,2126,1075,7175,2225,6675,585
Inventory3,0843,1043,2013,2543,2063,1923,0873,0182,8742,7152,5812,562
Net property, plant and equipment5,4595,2665,3665,0024,8414,6944,8174,4394,3064,2264,2244,006
Other intangible assets1,3101,2871,2571,3811,3521,1671,1491,1201,1021,0591,0391,017
Long-term investments10,63010,52810,59510,70110,4679,6659,0608,6517,9197,0535,4715,839
Current liabilities5,5315,1084,3684,4253,6673,5673,9443,6613,5093,5813,4233,599
Accounts payable1,1591,027939904724706790497562671607537
Long-term debt1,9871,9861,9861,9861,9851,9851,9841,9841,9841,9831,9831,983
Total debt2,7072,7062,7062,7062,705———————
Total liabilities10,0199,4459,3029,2128,2808,1588,4068,1167,8817,3797,1077,259
Total equity (incl. minority)31,71131,42431,25730,95829,93929,38829,35429,32628,20626,99125,97324,904
Retained earnings37,62136,42435,79735,04633,68032,38431,67330,75529,41527,98227,26026,101